The purpose of this study is to analyze the economic burden of persons with Alzheimer's disease (AD) and Parkinson's disease (PD) in Europe. On the basis of available data about the number of persons with dementia, their prevalence, and treatment and care costs, a mean cost burden is estimated for the year of 2030 and for the year of 2050 in Europe. The method of retrospective analysis of available sources was used; furthermore, analysis of database data such as WHO and Eurostat, which provide information about the number of older people and people with dementia; and specification of direct and indirect medical and nonmedical costs of patients with AD and PD from current studies was also used. The findings of this study confirm that the number of patients affected with AD and PD, as well as annual costs of the treatment and care of these patients, in the selected European countries are rapidly growing. The cost burden of both AD and PD in the selected European countries rises year by year, and by 2050, the cost burden of both diseases in fact will be almost two times higher in comparison with the year of 2010. In 2050, the overall mean cost burden is estimated to reach 357 billion Euros. The European Union calls for a joint initiative in the development of a uniformed strategic plan in the fight against dementia.

Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic

Biomedical Research Centrum University Hospital Hradec Kralove Hradec Kralove Czech Republic

Center of Basic and Applied Research Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Department of Chemistry Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic

Department of Economics Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Citace poskytuje Crossref.org

Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer's Disease

Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review

Enhancing Cognitive Performance of Healthy Czech Seniors through Non-Native Language Learning-A Mixed-Methods Pilot Study

Impact of Learning a Foreign Language on the Enhancement of Cognitive Functions Among Healthy Older Population

Effectiveness of the dog therapy for patients with dementia - a systematic review

Derivatives of the β-Crinane Amaryllidaceae Alkaloid Haemanthamine as Multi-Target Directed Ligands for Alzheimer's Disease

Nitrendipine and Dementia: Forgotten Positive Facts?

The direct costs of multiple sclerosis-study in the Czech Republic

Exploring assistive technology as a potential beneficial intervention tool for people with Alzheimer's disease - a systematic review

Economic analysis of acupuncture for migraine prophylaxis

Learning a Foreign Language: A Review on Recent Findings About Its Effect on the Enhancement of Cognitive Functions Among Healthy Older Individuals

Technological Solutions for Older People with Alzheimer's Disease: Review

PPI Long Term Use: Risk of Neurological Adverse Events?

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy

Cognitive decline in normal aging and its prevention: a review on non-pharmacological lifestyle strategies